The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
Fiverr (FVRR)
Consensus Price Target: $32.56 (48.6% implied return)
Based in Tel Aviv, Fiverr (NYSE: FVRR) operates a fixed price global freelance marketplace for digital services.
Why Does FVRR Give Us Pause?
- Active Buyers have declined by 8.1% annually over the last two years, suggesting it may need to revamp its features or user experience to stay competitive
- Estimated sales growth of 7% for the next 12 months implies demand will slow from its three-year trend
- Excessive marketing spend signals little organic demand and traction for its platform
At $21.91 per share, Fiverr trades at 8.8x forward EV/EBITDA. To fully understand why you should be careful with FVRR, check out our full research report (it’s free).
Comcast (CMCSA)
Consensus Price Target: $39.77 (25.2% implied return)
Formerly known as American Cable Systems, Comcast (NASDAQ: CMCSA) is a multinational telecommunications company offering a wide range of services.
Why Are We Out on CMCSA?
- Sluggish trends in its domestic broadband customers suggest customers aren’t adopting its solutions as quickly as the company hoped
- Anticipated sales growth of 2.4% for the next year implies demand will be shaky
- Underwhelming 8.6% return on capital reflects management’s difficulties in finding profitable growth opportunities
Comcast is trading at $31.76 per share, or 7.1x forward P/E. Check out our free in-depth research report to learn more about why CMCSA doesn’t pass our bar.
One Stock to Buy:
Natera (NTRA)
Consensus Price Target: $197.79 (29.9% implied return)
Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.
Why Are We Backing NTRA?
- Average unit sales growth of 21% over the past two years reflects steady demand for its products
- Adjusted operating profits increased over the last two years as the company gained some leverage on its fixed costs and became more efficient
- Free cash flow margin is now positive, indicating the company has achieved financial self-sustainability
Natera’s stock price of $152.28 implies a valuation ratio of 9.3x forward price-to-sales. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
